Transcatheter aortic valve implantation: from fantasy to reality

Journal of Cardiothoracic Surgery

Geoffrey Berg³  Vipin Zamvar¹  Renzo Pessotto¹  Tristan D Yan⁴  Sai Prasad¹  Edward T Brackenbury¹  Billy McWilliams²  Kasra Shaikhrezai³ 

[1] Department of Cardiothoracic Surgery, Royal infirmary of Edinburgh, Edinburgh, UK;Department of Anaesthetics, Intensive Care & Pain Management, Cardiff University, Cardiff, UK;Department of Cardiothoracic Surgery, Golden Jubilee National Hospital, Glasgow, Clydebank G81 4DY, UK;Department of Cardiothoracic Surgery, Royal Prince Alfred Hospital, Sydney, Australia

关键词: Evidence-based practice;    Technology;    Transcatheter Aortic Valve Implantation (TAVI);   

Others  :  811401
DOI  :  10.1186/1749-8090-9-43

 received in 2013-12-18, accepted in 2014-03-04,  发布年份 2014

【 摘 要 】

Increased life expectancy has led to the presentation of more complicated patients in old age for the replacement of the aortic valve. The emergence of Transcatheter Aortic Valve Implantation (TAVI) was considered as a significant breakthrough in the management of symptomatic, moribund patients suffering from aortic valve stenosis who had been rejected for surgical intervention. A novel technology often has a long journey from the point at which it is created to its every-day-use. It is now obvious that TAVI practice in multiple institutes around the world has gone beyond the evidence. Serious concerns have been raised questioning the current TAVI practice. Analysis of future TAVI use may assist clinicians and healthcare managers to understand and deploy this technology in accordance with the evidence.

【 授权许可】

   
2014 Shaikhrezai et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Cribier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F, Derumeaux G, Anselme F, Laborde F, Leon MB: Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation 2002, 106:3006-3008.
• [2]Gruentzig A: An odyssey in transcatheter aortic implantation. http://www.escardio.org/congresses/esc-2010/congress-news/Pages/tavi.aspx webcite
• [3]Briggs A, Sculpher M: An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998, 13(4):397-409.
• [4]Fenn J: When to leap on the hype cycle. https://www.gartner.com/doc/484408 webcite
• [5]OCEBM Levels of Evidence Working Group: “The Oxford levels of evidence 2”. Oxford Centre for Evidence-Based Medicine; http://www.cebm.net/index.aspx?o=5653 webcite
• [6]Van Brabant H, Neyt M, Hulstaert F: Transcatheter aortic valve implantation (TAVI): risky and costly. BMJ 2012, 345:e4710.
• [7]Leon MB, Smith CR, Mack JM, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard AD, Bavaria JE, Herrmann HC, Douglas PS, Petersen JL, Akin JJ, Anderson WN, Wang D, Pocock S, PARTNER Trial Investigators: Transcatheter Aortic-Valve Implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010, 363(17):1597-1607.
• [8]Smith CR, Leon MB, Mack JM, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Williams M, Dewey T, Kapadia S, Babaliaros V, Thourani VH, Corso P, Pichard AD, Bavaria JE, Herrmann HC, Akin JJ, Anderson WN, Wang D, Pocock SJ, PARTNER Trial Investigators: Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011, 364(23):2187-2198.
• [9]Kodali SK, Williams MR, Smith CR, Svensson LG, Webb JG, Makkar RR, Fontana GP, Dewey TM, Thourani VH, Pichard AD, Fischbein M, Szeto WY, Lim S, Greason KL, Teirstein PS, Malaisrie SC, Douglas PS, Hahn RT, Whisenant B, Zajarias A, Wang D, Akin JJ, Anderson WN, Leon MB, PARTNER Trial Investigators: Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med 2012, 366(18):1686-1695.
• [10]Makkar RR, Fontana GP, Jilaihawi H, Kapadia S, Pichard AD, Douglas PS, Thourani VH, Babaliaros VC, Webb JG, Herrmann HC, Bavaria JE, Kodali S, Brown DL, Bowers B, Dewey TM, Svensson LG, Tuzcu M, Moses JW, Williams MR, Siegel RJ, Akin JJ, Anderson WN, Pocock S, Smith CR, Leon MB, PARTNER Trial Investigators: Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl J Med 2012, 366(18):1696-1704.
• [11]Yan TD, Bannon PG: Transapical aortic valve implantation – A paradigm for innovation and collaboration in modern cardiac surgery. Ann Cardiothorac Surg 2012, 1(2):114.
• [12]Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Barón-Esquivias G, Baumgartner H, Borger MA, Carrel TP, De Bonis M, Evangelista A, Falk V, Lung B, Lancellotti P, Pierard L, Price S, Schäfers HJ, Schuler G, Stepinska J, Swedberg K, Takkenberg J, Von Oppell UO, Windecker S, Zamorano JL, Zembala M: Guidelines on the management of valvular heart disease (version 2012). Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC); European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2012, 33(19):2451-2496.
• [13]Nainggolan L: Germany Tops TAVI Table, But Room for Growth Remains. [http://www.medscape.com/viewarticle/752780 webcite]
• [14]Beckmann A, Hamm C, Figulla HR, Cremer J, Kuck KH, Lange R, Zahn R, Sack S, Schuler GC, Walther T, Beyersdorf F, Böhm M, Heusch G, Funkat AK, Meinertz T, Neumann T, Papoutsis K, Schneider S, Welz A, Mohr FW, GARY Executive Board: The German Aortic Valve Registry (GARY): a nationwide registry for patients undergoing invasive therapy for severe aortic valve stenosis. Thorac Cardiovasc Surg 2012, 60(5):319-325.
• [15]Dewey TM, Brown DL, Das TS, Ryan WH, Fowler JE, Hoffman SD, Prince SL, Herbert MA, Culica D, Mack MJ: High-risk patients referred for transcatheter aortic valve implantation: management and outcomes. Ann Thorac Surg 2008, 86(5):1450-1456.
• [16]Subramanian S, Rastan AJ, Holzhey D, Haensig M, Kempfert J, Borger MA, Walther T, Mohr FW: Conventional aortic valve replacement in transcatheter aortic valve implantation candidates: a 5-year experience. Ann Thorac Surg 2012, 94(3):726-729.
• [17]Moat NE, Ludman P, de Belder MA, Bridgewater B, Cunningham AD, Young CP, Thomas M, Kovac J, Spyt T, MacCarthy PA, Wendler O, Hildick-Smith D, Davies SW, Trivedi U, Blackman DJ, Levy RD, Brecker SJ, Baumbach A, Daniel T, Gray H, Mullen MJ: Long-term outcomes after Transcatheter Aortic Valve Implantation in high-Risk patients with severe aortic stenosis: the U.K. TAVI (United Kingdom Transcatheter Aortic Valve Implantation) Registry. J Am Coll Cardiol 2011, 58(20):2130-2138.
• [18]Scottish Government: Final report of the TAVI review group – national planning forum subgroup. 2010. http://www.scotland.gov.uk/Resource/0039/00392167.pdf webcite
• [19]Schaff HV: Transcatheter aortic-valve implantation–at what price? N Engl J Med 2011, 364(23):2256-2258.
• [20]National Institute for Health and Clinical Excellence: Transcatheter Aortic Valve Implantation for Aortic Stenosis. [IPG 421] London: National Institute for Health and Clinical Excellence; 2012.
• [21]Iung B, Cachier A, Baron G, Messika-Zeitoun D, Delahaye F, Tornos P, Gohlke-Bärwolf C, Boersma E, Ravaud P, Vahanian A: Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery? Eur Heart J 2005, 26(24):2714-2720.
• [22]Devi S: US physicians urge end to unnecessary stent operations. Lancet 2011, 378:651-652.